Radioligand Therapy With 177Lu-PSMA-617 – A Novel Therapeutic Possibility on the Horizon in Men With Metastatic Castration Resistant Prostate Cancer.

We are seeing more and more novel therapies being developed to treat castrate resistant metastatic prostate cancer (mCRPC). One such therapy involves theranostic (individualized therapies for various diseases, and to combine diagnostic and therapeutic capabilities into a single agent) concepts using radiolabeled ligands of the prostate-specific membrane antigen (PSMA). In a recent study, designed to [...]

Radiotherapy Might Not Extend Survival In Men With Prostate Cancer Who Are Under 70 Years Old

Increasingly, we are seeing younger men diagnosed with prostate cancer and with bone metastases. One of the more common therapies, radiotherapy is recognized for its effect on local control of bone metastases, but whether it could prolong overall survival, the gold standard is still controversial. Researchers retrospectively evaluated 113 men with prostate cancer and bone [...]

Understanding Prostate Cancer Clinical Trials – Types and Stages

The decision to enroll in a clinical trial should involve a discussion between the person with prostate cancer and that individual’s physician. Your participation should depend on many factors, including your motivation for enrolling in a trial, the stage of your prostate cancer, and the trials available and its phase. When you decide to enroll in a clinical [...]

Happy DNA Day!

Happy DNA Day! First celebrated in 2003 by proclamation of the Senate and the House of Representatives, the holiday commemorates the day James Watson, Francis Crick, Maurice Wilkins and Rosalind Franklin first published their papers on the structure of DNA. The reason for the proclamation In 2003 it was announced that the Human Genome Project [...]

By |2021-02-17T10:41:16-05:00April 25th, 2016|Advanced Prostate Cancer, Advocacy, Uncategorized|0 Comments

Recurring Prostate Cancer- What ADT Treatment Schedule Is Superior?

 One of the many constantly recurring topics that we discuss is over the efficacy of intermittent hormone deprivation therapy (IAD) as opposed to continuous hormone deprivation therapy (CAD). Which therapy is better has been debated for at least ten years. The debate still rages over the question of efficacy, or survival as well as the [...]

Go to Top